Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes

Table 2 Clinical outcomes of all patients with TVD stratified according to diabetes mellitus

	Diabetes (n = 1040)	Non-diabetes (n = 1694)	Adjusted HR (95% CI)^*	P
All-cause death	42 (4.0)	29 (1.7)	1.82 (1.07–3.11)	0.026
Myocardial infarction	156 (15.0)	156 (9.2)	1.56 (1.23–1.98)	< 0.001
Repeat revascularization	233 (22.4)	350 (20.7)	1.10 (0.92–1.31)	0.265
Angina pectoris readmission	159 (15.3)	271 (16.0)	0.99 (0.81–1.23)	0.998
Heart failure readmission	114 (11.0)	104 (6.1)	1.49 (1.11–1.99)	0.007
Stroke	14 (1.3)	28 (1.7)	0.67 (0.33–1.37)	0.279
MACCE	361 (34.7)	492 (29.0)	1.17 (1.01–1.35)	0.031

*Covariates were adjusted for age, sex, smoking, hypertension, dyslipidemia, chronic kidney disease, prior myocardial infarction, left ventricular ejection fraction, ACS and revascularization in hospital
ACS acute coronary syndrome, CI confidence interval(s), HR hazard ratio, MACCE major adverse cardiac and cerebrovascular events, TVD three-vessel disease

ISSN: 1475-2840